{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T19:07:12Z","timestamp":1774465632111,"version":"3.50.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2007,2,1]],"date-time":"2007-02-01T00:00:00Z","timestamp":1170288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The American Journal of Cardiology"],"published-print":{"date-parts":[[2007,2]]},"DOI":"10.1016\/j.amjcard.2006.11.007","type":"journal-article","created":{"date-parts":[[2006,12,28]],"date-time":"2006-12-28T12:06:58Z","timestamp":1167307618000},"page":"68-79","source":"Crossref","is-referenced-by-count":56,"special_numbering":"S","title":["Weight Management for Type 2 Diabetes Mellitus: Global Cardiovascular Risk Reduction"],"prefix":"10.1016","volume":"99","author":[{"given":"Michelle","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis J.","family":"Aronne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjcard.2006.11.007_bib1","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1001\/jama.295.13.1549","article-title":"Prevalence of overweight and obesity in the United States, 1999\u20132004","volume":"295","author":"Ogden","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.007_bib2","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1001\/jama.289.1.76","article-title":"Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001","volume":"289","author":"Mokdad","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.007_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1385\/ENDO:29:1:109","article-title":"Epidemiology, trends, and morbidities of obesity and the metabolic syndrome","volume":"29","author":"Bray","year":"2006","journal-title":"Endocrine"},{"key":"10.1016\/j.amjcard.2006.11.007_bib4","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1161\/01.ATV.0000216787.85457.f3","article-title":"Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss","volume":"26","author":"Poirier","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.amjcard.2006.11.007_bib5","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/07853890500383895","article-title":"Is visceral obesity the cause of the metabolic syndrome?","volume":"38","author":"Despres","year":"2006","journal-title":"Ann Med"},{"key":"10.1016\/j.amjcard.2006.11.007_bib6","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1210\/jc.2004-1711","article-title":"Adiponectinemia in visceral obesity: impact on glucose tolerance and plasma lipoprotein and lipid levels in men","volume":"90","author":"Cote","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjcard.2006.11.007_bib7","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1210\/jcem.86.5.7463","article-title":"Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia","volume":"86","author":"Weyer","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.amjcard.2006.11.007_bib8","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.ijo.0803355","article-title":"Adiponectin, insulin resistance and clinical expression of the metabolic syndrome in patients with Type 2 diabetes","volume":"31","author":"Mojiminiyi","year":"2007","journal-title":"Int J Obes (Lond)"},{"key":"10.1016\/j.amjcard.2006.11.007_bib9","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1161\/01.ATV.13.3.415","article-title":"Plasminogen activator inhibitor activity in diabetic and nondiabetic survivors of myocardial infarction","volume":"13","author":"Gray","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"10.1016\/j.amjcard.2006.11.007_bib10","series-title":"The Practical Guide: Identification, Evaluation, and Treatment of Overweight and Obesity in Adults","year":"2000"},{"key":"10.1016\/j.amjcard.2006.11.007_bib11","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1056\/NEJMra012586","article-title":"Obesity","volume":"346","author":"Yanovski","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.007_bib12","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/01.mco.0000232914.14978.c5","article-title":"Bariatric surgery: effects on glucose homeostasis","volume":"9","author":"Rubino","year":"2006","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.amjcard.2006.11.007_bib13","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.007_bib14","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJM200105033441801","article-title":"Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance","volume":"344","author":"Tuomilehto","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.007_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","author":"Knowler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.007_bib16","doi-asserted-by":"crossref","first-page":"611","DOI":"10.7326\/0003-4819-142-8-200504190-00009","article-title":"The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program Randomized Trial","volume":"142","author":"Orchard","year":"2005","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.007_bib17","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/07315724.2003.10719316","article-title":"Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies","volume":"22","author":"Anderson","year":"2003","journal-title":"J Am Coll Nutr"},{"key":"10.1016\/j.amjcard.2006.11.007_bib18","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.2337\/diacare.20.10.1503","article-title":"A randomized controlled trial of weight reduction and exercise for diabetes management in older African-American subjects","volume":"20","author":"Agurs-Collins","year":"1997","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.007_bib19","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/archinte.1987.00370100063012","article-title":"Long-term effects of modest weight loss in type II diabetic patients","volume":"147","author":"Wing","year":"1987","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjcard.2006.11.007_bib20","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.2337\/diacare.27.7.1570","article-title":"Translating lifestyle intervention to practice in obese patients with type 2 diabetes: improving control with activity and nutrition (ICAN) study","volume":"27","author":"Wolf","year":"2004","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.amjcard.2006.11.007_bib21","first-page":"CD004095","article-title":"Long-term non-pharmacological weight loss interventions for adults with type 2 diabetes mellitus","author":"Norris","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.amjcard.2006.11.007_bib22","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/oby.2006.84","article-title":"The Look-AHEAD study: a description of the lifestyle intervention and the evidence supporting it","volume":"14","year":"2006","journal-title":"Obesity"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.007_bib23","doi-asserted-by":"crossref","first-page":"553S","DOI":"10.1002\/j.1550-8528.1995.tb00227.x","article-title":"Sibutramine: a novel new agent for obesity treatment","volume":"3","author":"Ryan","year":"1995","journal-title":"Obes Res"},{"key":"10.1016\/j.amjcard.2006.11.007_bib24","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0278-5846(88)90003-6","article-title":"The pharmacology of sibutramine hydrocholoride (BTS 54 524), a new antidepressant which induces rapid noradrenergic down regulation","volume":"12","author":"Buckett","year":"1988","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.amjcard.2006.11.007_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1467-789x.2000.00020.x","article-title":"An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action","volume":"1","author":"Nisoli","year":"2000","journal-title":"Obes Rev"},{"issue":"suppl","key":"10.1016\/j.amjcard.2006.11.007_bib26","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/sj.ijo.0801930","article-title":"When, for whom and how to use sibutramine?","volume":"25","author":"Astrup","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.amjcard.2006.11.007_bib27","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1056\/NEJMoa050156","article-title":"Randomized trial of lifestyle modification and pharmacotherapy for obesity","volume":"353","author":"Wadden","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.007_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1046\/j.1463-1326.2000.00071.x","article-title":"Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomized, double-blind, placebo-controlled study","volume":"2","author":"Finer","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2006.11.007_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1463-1326.2000.00081.x","article-title":"Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus","volume":"2","author":"Fujioka","year":"2000","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2006.11.007_bib30","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2337\/diacare.26.1.125","article-title":"A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin","volume":"26","author":"McNulty","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.007_bib31","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2337\/diacare.28.4.942","article-title":"Effect of sibutramine on weight management and metabolic control in type 2 diabetes","volume":"4","author":"Vettor","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.007_bib32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jama.281.3.235","article-title":"Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial","volume":"281","author":"Davidson","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.007_bib33","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0140-6736(97)11509-4","article-title":"Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients","volume":"352","author":"Sjostrom","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.007_bib34","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.007_bib35","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.2337\/diacare.25.6.1033","article-title":"Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes; a one year randomized controlled trial","volume":"25","author":"Kelley","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.007_bib36","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2337\/diacare.25.7.1123","article-title":"Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin","volume":"25","author":"Miles","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.007_bib37","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/j.1464-5491.2004.01474.x","article-title":"A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin","volume":"22","author":"Berne","year":"2005","journal-title":"Diabet Med"},{"key":"10.1016\/j.amjcard.2006.11.007_bib38","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.ijo.0800468","article-title":"Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes","volume":"21","author":"Wolever","year":"1997","journal-title":"Int J Obes"},{"key":"10.1016\/j.amjcard.2006.11.007_bib39","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/jama.290.4.486","article-title":"Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial","volume":"290","author":"Chiasson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.007_bib40","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0195-668X(03)00468-8","article-title":"Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies","volume":"25","author":"Hanefeld","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjcard.2006.11.007_bib41","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/j.1550-8528.1998.tb00314.x","article-title":"Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes","volume":"6","author":"Lee","year":"1998","journal-title":"Obes Res"},{"key":"10.1016\/j.amjcard.2006.11.007_bib42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1463-1326.2002.00181.x","article-title":"Evaluation of the safety and efficacy of sibutramine, orlistat, and metformin in the treatment of obesity","volume":"4","author":"Gokcel","year":"2002","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2006.11.007_bib43","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1053\/meta.2001.28078","article-title":"Beneficial effects of metformin in normoglycemic morbidly obese adolescents","volume":"50","author":"Kay","year":"2001","journal-title":"Metabolism"},{"key":"10.1016\/j.amjcard.2006.11.007_bib44","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.2337\/diacare.28.5.1092","article-title":"Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes","volume":"28","author":"DeFronzo","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.007_bib45","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.physbeh.2006.04.001","article-title":"Amylinergic control of food intake","volume":"89","author":"Lutz","year":"2006","journal-title":"Physiol Behav"},{"key":"10.1016\/j.amjcard.2006.11.007_bib46","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1046\/j.1463-1326.2003.00295.x","article-title":"Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type 2 diabetes approaching glycaemic targets","volume":"5","author":"Hollander","year":"2003","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.amjcard.2006.11.007_bib47","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"2","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.amjcard.2006.11.007_bib48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/15209150252924094","article-title":"Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes","volume":"4","author":"Ratner","year":"2002","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.amjcard.2006.11.007_bib49","unstructured":"Aronne LJ, Wadden TA, Klein S, Smith S, Halseth A, Kesty N, Burns C, Weyer C. Pramlintide treatment for obesity elicited progressive weight loss when used with a structured lifestyle intervention program: a randomized controlled trial. Presented at NAASO, The Obesity Society, Annual Scientific Meeting; October 24\u201326, 2006; Boston, Massachusetts."},{"key":"10.1016\/j.amjcard.2006.11.007_bib50","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0140-6736(05)66374-X","article-title":"Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience for the RIO-Europe study","volume":"365","author":"van Gaal","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.007_bib51","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002130050953","article-title":"Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors","volume":"143","author":"Williams","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.amjcard.2006.11.007_bib52","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/sj.bjp.0704767","article-title":"Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol","volume":"136","author":"Kirkham","year":"2002","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.amjcard.2006.11.007_bib53","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.2337\/diabetes.54.10.2838","article-title":"Activation of the peripheral endocannabinoid system in human obesity","volume":"54","author":"Engeli","year":"2005","journal-title":"Diabetes"},{"key":"10.1016\/j.amjcard.2006.11.007_bib54","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/35071088","article-title":"Leptin-regulated endocannabinoids are involved in maintaining food intake","volume":"410","author":"Di Marzo","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.amjcard.2006.11.007_bib55","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/sj.ijo.0802583","article-title":"CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity","volume":"28","author":"Ravinet-Trillou","year":"2004","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.1016\/j.amjcard.2006.11.007_bib56","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1001\/jama.295.7.761","article-title":"Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial","volume":"295","author":"Pi-Sunyer","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.amjcard.2006.11.007_bib57","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1016\/S0140-6736(06)69571-8","article-title":"Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study","volume":"368","author":"Scheen","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.amjcard.2006.11.007_bib58","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa044537","article-title":"Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia","volume":"353","author":"Despres","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjcard.2006.11.007_bib59","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1124\/mol.63.4.908","article-title":"The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa\/fa rats and in cultured adipocyte cells","volume":"63","author":"Bensaid","year":"2003","journal-title":"Mol Pharmacol"}],"container-title":["The American Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914906021990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002914906021990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,10]],"date-time":"2019-01-10T13:52:18Z","timestamp":1547128338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002914906021990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2007,2]]}},"alternative-id":["S0002914906021990"],"URL":"https:\/\/doi.org\/10.1016\/j.amjcard.2006.11.007","relation":{},"ISSN":["0002-9149"],"issn-type":[{"value":"0002-9149","type":"print"}],"subject":[],"published":{"date-parts":[[2007,2]]}}}